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ABSTRACT
Venous oxygen saturation (Yv) in cerebral veins and the cerebral metabolic rate of
oxygen (CMRO2) are important indicators for brain function and disease. Phase-susceptibility
measurements in magnetic resonance imaging (MRI) have been used to quantify Yv in candidate
cerebral veins. However, currently there is no method to quantify regional CMRO 2 using MRI.
Here we propose a novel technique to quantify CMRO2 from independent MRI estimates of Yv
and cerebral blood flow (CBF). Our approach used standard gradient-echo (GRE) and arterial
spin labeling (ASL) to make these measurements. Results for in vivo Y, and CMRO2 estimates
on human subjects are presented from application of our technique at 3 Tesla (3T). We also
extended our method to high-field human imaging at 7 Tesla (7T), which allows us to take
advantage of improved signal-to-noise ratio (SNR) for the same scan duration to achieve higher-
resolution analysis of vessels of interest. While the higher field strength poses additional
challenges, such as increased main field and excitation field inhomogeneities as well as more
severe susceptibility artifacts, initial results suggest that substantial benefits can be realized with
phase-based regional oxygen metabolism in MRI at high field.
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Chapter 1
Introduction
While magnetic resonance imaging (MRI) does not offer a direct contrast mechanism for
tissue oxygenation or oxygen consumption, the complicated physiology of blood flow and
oxygenation in the brain does modulate the MRI signal. Neural activity creates local changes in
cerebral hemodynamics, which in turn can be detected using functional magnetic resonance
imaging (fMRI) techniques through the blood-oxygen-level-dependent (BOLD) response [1, 2].
The BOLD effect is a complex function of cerebral hemodynamics, including cerebral blood
flow (CBF), cerebral blood volume (CBV), and oxygen consumption [3, 4], and relative changes
in this hemodynamic response are used as a surrogate to detect neuronal activity.
Despite recent advances in high-resolution imaging, BOLD fMRI offers limited temporal
and spatial resolution of brain function. Ideally, measured hemodynamic changes reflect
physiological alterations in the capillary bed where oxygen exchange between the cerebral
vessels and tissue occurs during neural activation. However, the specificity of the technique is
difficult to assess because measurements may be contaminated by larger vessels with higher
metabolic activity [1, 5]. This limits localization of activation regions and estimation of their
extent, especially as exact models relating the BOLD signal to underlying physiological changes
are difficult to establish.
Unlike the BOLD mechanism for contrast, venous oxygen saturation (Y,) and the
cerebral metabolic rate of oxygen (CMRO 2) are quantitative physiological parameters. Y, is a
measure of the percentage oxygen saturation remaining in cerebral veins, and CMRO 2
(gmol/g/min) is a metabolic parameter that quantifies the rate of oxygen expenditure in brain
tissue. As fundamental physiological parameters, both are important indicators of tissue
viability. Absolute measurements of CMIRO 2 and Yv are thus expected to be intrinsically linked
to underlying physiological processes [6, 7], and regional estimates of these parameters would
provide new information about neural function and modulation in disease states of the brain.
Currently, there is no direct method to measure regional Y, and CMRO2 with MRI in the
human brain. Accepted values for Y, and CMRO 2 in the literature are reported by positron
emission tomography (PET) studies [8] and have identified these parameters as critical markers
in disease states such as stroke and tumor [9, 10]. However, PET imaging is a comparatively
low spatial-resolution technique and involves injection of a radioactive label, which requires
equipment that is not widely available. MRI-based methods have been proposed to measure
oxygenation in the brain, including the combination of fMRI BOLD and CBF measurements for
calibrated estimates of CMRO2 changes [11]. These calibrated fMRI techniques, however, only
measure relative changes in metabolism and depend on a physiological challenge such as
hypercapnia, or inhalation of air mixed with CO2. A recent alternate approach based on T2
relaxation in MRI, T2-relaxation-under-spin-tagging (TRUST), allows quantification of absolute
Y, and CMRO2, but only offers global measurements from the whole brain [12].
Our goal is provide high-resolution, quantitative measurements of local CMRO2 and Y,
currently unavailable in MRI. Here, we present a novel approach to quantify localized CMRO2
from independent measures of Y, and CBF. MR phase-susceptibility techniques have been used
to measure global and regional venous oxygenation in resting and activated states of the brain at
3 Tesla (3T) [13, 14]. Our measurements of venous oxygen saturation are based on innate
susceptibility differences between cerebral blood vessels and the surrounding brain parenchyma.
The measured susceptibility differences are related to oxygen saturation because the
intravascular concentration of deoxyhemoglobin (dHb), a paramagnetic species, changes with
vessel oxygenation. We acquire gradient-echo phase maps using MRI, from which susceptibility
changes and the corresponding Yv can be quantified for candidate veins amenable to our
assumptions about vessel geometry.
To quantify CMRO2, we acquire an additional CBF measurement using arterial spin
labeling (ASL) with MRI. ASL includes a noninvasive tagging scheme that magnetically labels
arterial blood flowing into an imaging slice and can provide a quantitative perfusion map for the
slice [15]. We use ASL to measure local tissue CBF representative for our cerebral vessels of
interest. CMRO 2 is then quantified on a regional basis through a known relationship with CBF
and Yv, the Fick principle of arterio-venous difference [5, 16]. Here we present results for Y,
and CMRO2 using this method in human subjects at 3T.
The power of our technique is that it uses standard sequences readily available on clinical
scanners and can be generalized for improved local measurements throughout the brain. We
have extended our technique to high field at 7 Tesla (7T), which offers improved signal-to-noise
ratio (SNR) that allows for higher-resolution imaging. Challenges of high-field imaging include
more severe field inhomogeneity, phase wrapping, and background susceptibility gradients. We
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address some of these issues to take advantage of improved resolution at high field and present
preliminary in vivo measurements of Y, and CMRO 2 at 7T. In addition, recent developments in
quantitative susceptibility mapping [17-22] suggest that our method can be generalized to a
larger set of veins without the constraints on vessel geometry or orientation present in the current
technique. We will discuss these promising improvements to our method as well as potential
applications of our high-resolution measures of local Yv and CMRO2 in future work.
The work presented in this thesis was accepted as an oral presentation at the 1 8th annual
meeting of the International Society for Magnetic Resonance in Medicine (ISMIRM), held
recently in Stockholm, Sweden.
Chapter 2
Background
2.1 Phase-susceptibility measurements of vessel oxygenation
Magnetic susceptibility (x) is a quantitative measure of the magnetization of a material in
response to an applied magnetic field. For materials whose magnetization M is linearly related
to the applied magnetic field H, susceptibility is a dimensionless quantity defined as X = M / H,
where M and H both have units of Amperes/m [23]. Materials can be classified according to
susceptibility as paramagnetic (x>O), diamagnetic (x<O), and ferromagnetic (x>>O).
Paramagnetic materials tend to increase the surrounding applied field and diamagnetic materials
tend to decrease this field. Most materials important in MRI are weakly magnetic with | X | < 0,
and values for common biological materials in MRI are presented in Fig 1 [23].
Human tissues (-11.0 to -7.0)
-10 0 +10
X 10-6
H20 dHb Air
(-9.05) (+0.15) (+0.36)
Figure 1. Absolute susceptibility of common biological materials in MRI. Deoxyhemoglobin is denoted dHb.
The susceptibility difference (AX) between venous blood vessels and the surrounding
brain tissue is related to venous oxygenation (Y,), our parameter of interest. This section
describes how our method uses phase measurements to quantify this susceptibility shift and thus
the underlying vessel oxygenation.
2.1.1 Susceptibility shift between a vein and background tissue is related to
venous oxygen saturation
We are motivated to measure the susceptibility shift between a vein and the surrounding
tissue because it provides endogenous oxygenation-dependent contrast in vivo. Hemoglobin in
red blood cells is the primary carrier of oxygen in the body, and its reduced form,
deoxyhemoglobin (dHb), is found in venous blood. Decreased oxygenation corresponds to
increased concentration of dHb, which is known to be paramagnetic. This reflected in the
increased susceptibility of venous blood with respect to the surrounding brain parenchyma.
From the measured susceptibility shift AXvein-tissue, we quantified oxygen saturation Yv for
each vessel using Equation 1 [13]. Here we assumed AXdo = 0.18 ppm (cgs) as the susceptibility
difference between fully deoxygenated and fully oxygenated blood [24], where implicitly the
tissue has the same susceptibility as fully oxygenated blood. We also assumed literature values
for hematocrit, or the percent fraction of blood volume that consists of red blood cells, where Hct
= 0.42 for males and Hct = 0.38 for females [25].
AXvein-tissue = AXdo - Hct - (1 - Yv) (Eq. 1)
2.1.2 Relationship between local susceptibility shift and magnetic field shift
MRI is sensitive to local perturbations in the main magnetic field (Bo), including those
that arise from susceptibility effects. We are interested in the field difference between the inside
of the vein of interest and the surrounding tissue, ABvein-tissue. Although this local field shift is
related to the underlying susceptibility difference AXvei,.issue we are trying to measure, it is also
highly dependent on vessel geometry and orientation. For this reason, the inversion from a field
map to susceptibility map is not straightforward.
Recent developments have allowed for rapid simulation of the expected field map from
the underlying susceptibility distribution [26, 27]. This is described in Equation 2, where AB is
expressed in the image domain with spatial coordinates and FT refers to a three-dimensional
Fourier Transform. Here, the magnitude of a k-space vector, k2 = k+ k + k!, is calculated for
each point in the k-space (Fourier) domain, and kz refers to the component of the k-space vector
parallel to the main magnetic field [19].
AB(x, y, z) = BO -FT- (i- k) FT {X(x,y,z)} (Eq. 2)
Although Equation 2 allows for fast forward calculation of the field map, the inversion
problem critical for our technique is difficult in general. The inversion is ill-posed for a conical
region in k-space of angle 54.10, where the factor 1 - = 0 , because the k-space data is3 k 2
effectively lost in that region.
In our method, we focused on candidate veins for which the inversion from measured
field shift to susceptibility shift is straightforward. Weisskoff and Kiihne first developed an MRI
method to quantify absolute susceptibility by imaging phase of paramagnetic agents in
cylindrical tubes, including red blood cells at various oxygenations [24]. Haacke applied this
technique to cerebral vessels in vivo [13], and we adopted similar assumptions about vessel
geometry and orientation in our method. Here we used axial imaging slices, which are
orthogonal to the direction of the main magnetic field, Bo. We restricted our analysis to through-
plane vessels parallel to Bo, with a diameter much smaller than the length of the vessel segment
along the main field (Fig 1).
Figure 2. (a) Schematic of geometry and orientation of candidate through-plane vessels in axial imaging plane. (b)
Example of coronal view of candidate vessel in vivo. The blue arrow indicates slice from which phase
measurements are made. S = superior, R = subj ect right, L = subj ect left, I = inferior.
For the purpose of estimating field changes due to susceptibility variation between the
inside and outside of the vein, such vessels are approximated as infinite cylinders, for which
there is a simple analytical relationship between AB and AX. In this case, the ill-conditioned
relationship in Equation 2 reduces to a simple proportionality between AB and AX (Equation 3),
which dramatically simplifies the estimation of AX. This approximation holds well even if the
vessel is slightly tilted with respect to the main magnetic field, with less than 5% error in the
estimated oxygen saturation from simulation for vessel tilt of less than 100 [14].
ABvein.tissue = - 4 r -Xvein-tissue - BO (Eq. 3)3
2.1.3 Gradient-echo phase images reveal local field shifts
The gradient-echo (GRE) sequence in MRI uses a pair of bipolar gradients to create a
signal echo for imaging [28]. This image encoding method is summarized by a pulse sequence
diagram, which displays the relative timing of the radiofrequency (RF) excitation pulse, gradient
17
pulses, and the data sampling period or ADC. For the GRE sequence, a representative pulse
sequence diagram is shown in Fig 2, where acquisition parameters such as the flip angle (a4),
echo time (TE), and the repetition time (TR) determine the image contrast.
GRE imaging can be implemented as a relatively fast acquisition, i.e. one in which TR is
short, such that acquiring several hundred TR periods for an image with appropriate resolution
takes a few minutes. For our studies, we applied a standard implementation of GRE called Fast
Low-Angle Shot (FLASH) [29]. We also used first-order flow compensation, or gradient
moment nulling, in three directions to minimize flow-related artifacts from the blood in our
phase measurements [28].
RF t
G. (Slice)
Gy (Phase)
G. (Frequency)
ADC
TE
Figure 3. Pulse sequence diagram for gradient-echo acquisition. The flip angle is denoted a& and ADC represents
the signal readout at time TE.
With the assumptions previously described, local field shifts manifested in gradient-echo
phase images can be measured as a proxy for susceptibility measurements to quantify Y. The
resulting magnitude images are sensitive to T2* relaxation effects, i.e. the decay of the MR signal
during TE, including susceptibility-induced field perturbations between the vein and tissue.
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Since dHb in cerebral veins is paramagnetic, we expect the field inside the vessel to be increased
with respect to the brain parenchyma, so that cerebral veins have bright contrast in phase images.
The same vessels appear dark in GRE magnitude images because signal loss occurs due to
dephasing from ABvein.tissue.
We acquired gradient echo images at multiple echo times (TE), and measure phase
differences between the vessel and background tissue to determine the local field shift. The
phase evolves linearly with TE as described by the Larmor relationship in Equation 4, where y =
2.67 108 rad/(s -T) is the gyromagnetic ratio for a 1H proton.
A(vein-tissue = y - TE - ABvein-tissue (Eq.4)
2.2 Quantification of cerebral blood flow (CBF) with
arterial spin labeling (ASL)
To quantify regional neural metabolism, our technique uses arterial spin labeling (ASL) for
local measures of perfusion in the brain [30, 31]. In ASL, a tag image and control image are
generated. For the tag image, a 1800 inversion pulse is used to invert spins in arterial blood
before it reaches the imaging slice. The tag image is generated after a user-specified inflow time
(TI) during which labeled spins are carried by arterial blood into the imaging slice at a rate
proportional to local perfusion. A control image is then acquired with the same sequence
parameters but without the magnetic tagging of the blood. When the tag image is subtracted
from the control image, static spins cancel out, and each voxel in the difference image is
proportional to local cerebral blood flow (CBF), the rate of delivery of arterial blood [15].
2.2.1 PICORE-Q2TIPS acquisition avoids venous signal contamination and
transit delay effects
In our method, we used a pulsed ASL scheme with an echo-planar imaging (EPI)
acquisition. Our acquisition applied PICORE (proximal inversion with control for off-resonance
effects) tagging, which uses a spatially-selective pulse to invert spins flowing through a thick
band below the slice of interest to be imaged (Figure 3a) [32]. Because PICORE tagging only
uses one inversion band below the imaging slice, it is sensitive only to arterial blood flow. This
avoids potential venous blood contamination that can be a problem in other ASL tagging
schemes such as FAIR (flow sensitive alternating inversion recovery) that includes non-selective
inversion both below and above the imaging slice [15].
In pulsed ASL, there is a transit delay (6t) for flowing spins that arises from the necessary
gap between the inversion band and the imaging slice. This delay can create errors in
quantitative CBF measurements, especially in disease states of the brain in which the vascular
path is impaired. QUIPSS II (quantitative imaging of perfusion using a single subtraction) is a
refinement to the ASL sequence that mitigates transit delay effects. After the original inversion
pulse to label arterial blood, QUIPSS II applies a saturation pulse in the same location as the
inversion band at a time TI1 (Fig 4b) [33]. This ensures that the final perfusion only comes
from a blood tagged during the time period up to the specified TI1 , i.e. it effectively defines a
bolus of labeled spins with width TI1 . If the image is then acquired at a time TI2 after all the
labeled blood has enough time to travel to the imaging slice, we can avoid transit delay errors in
our quantitative perfusion map. That is, TI2 should be chosen such that TI2 > TI, + t.
b
1 I I IIi /t =T11 t =T'2
I. f.iti ilL--i- ------- L---- ------- L---- -------
Inversion Saturation Imaging
>t
Figure 4. (a) Axial positioning of imaging slices and inversion and saturation bands for PICORE-Q2TIPS ASL
acquisition. (b) QUIPSS II schematic illustrating application of saturation in the same location of inversion band at
time t = TI,. Imaging occurs after all tagged blood has reached the capillary bed in the imaging slice at time t = TI2.
Q2TIPS (QUIPSS II with thin-slice TI1 periodic saturation) replaces the single saturation
band in QUIPSS II with a train of saturation pulses at the distal end of the inversion band at a
time TI1 [34]. These saturation pulses have a thinner sinc slice profile to create sharper edges
than the thicker profile of the original saturation band, and offer improved B1 field homogeneity.
These refinements have been shown to improve the accuracy of quantitative CBF maps.
/mag( ing slices
ISaturation band
inversion Wand
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2.2.2 Calibration of ASL images for quantitative CBF
The PICORE-Q2TIPS acquisition provides a control-tag subtraction series that can be
averaged for a relative perfusion map. To calibrate the CBF measurement, we acquire an
additional scan with matched TR and TE to estimate the fully relaxed longitudinal magnetization
of arterial blood (MOB) on a voxel-by-voxel basis from the local tissue equilibrium magnetization.
The flow was then quantified from the averaged difference signal (AM) using Equation 5, where
CBF is measured in units of ml/100g/min [15].
AM = 2 MOB - CBF - TI1 - e-T2Tlb (Eq.5)
Here, TI and TI2 are parameters set by the user and TIb is the T1 relaxation constant of
blood. The factor of 2 arises because we subtract inverted spins in the tag image from the
control image, and the exponential term represents T1 decay that occurs until imaging at time TI2.
We have assumed Tib = 1684 ms at 3 Tesla [15], and Tib = 2000 ms at 7 Tesla [35]. Note that
AM is proportional to the bolus width TII, and to our measurement of interest, CBF.
2.3 The Fick principle of arterio-venous difference relates
CMRO2 to Yv and CBF
The Fick principle has been used to relate flow, the arterio-venous oxygenation gradient,
and oxygen consumption [5, 12]. We use the Fick principle to quantify CMRO 2 in
ptmol/100g/min from our previously described measurements. As described in Equation 6,
CMRO2 is proportional to the oxygen extraction fraction (OEF) and local perfusion around a
vessel of interest. OEF is calculated from Yv as in Equation 7, where we have assumed that
arterial blood is fully saturated (Ya = 100%). The total concentration of hemoglobin, [Hb], can
be calculated from the assumed hematocrit (Hct) values using Equation 8, where 0.016125g is
the micromolar mass of one Hb unit.
CMRO 2 = OEF - [Hb] - CBF -Ya (Eq.6)
OEF =Ya" (Eq. 7)
[Hb] = Hct (Eq.8)3.0 - 0.016125
Chapter 3
Methods
3.1 Phase-susceptibility measurements using 2D gradient-
echo at 3T
We acquired 10 axial slices with both magnitude and phase contrast using the 2D, flow-
compensated FLASH sequence detailed in Table 1. Here the listed acquisition time is for each
echo as they were acquired in separate scans to maintain flow compensations at all echo times.
Table 1. GRE sequence parameters at 3T
Sequence fl2dlr
TR (ms) 270
TE (ms) 10, 15, 20
Flip Angle (deg) 25
Acquisition time (min)
Field of view (mm)
Resolution (mm)
Bandwidth per pixel
(Hz/pix)
5:53
217 x 224
0.5 x 0.5 x 2.0
151
3.1.1 Selection of echo times (TE) for phase-susceptibility measurements
To optimize the range of GRE echo times, we simulated the expected phase difference
between the vessel and tissue for physiological oxygenation levels. This involved a tradeoff
between larger values for the accrued phase at longer TE's versus less T2* signal decay and less
phase wrapping at shorter TE's. As a compromise, we used echo times of TE = 5, 10, 15ms for
our 3T acquisition to avoid phase wrapping between the vessel and background tissue (Fig 4a),
while maintaining a maximum expected phase difference of between 2 and 3 radians for the
physiological range of Y, (50 - 75%) [14].
vein-tissue (rad)
a b
3------------------
--- 55%
2- 60%
-65%
1 *-70%
3T 7T
0 5 10 15 20 25 30 0 5 10 15 20 25 30
TE (ms) TE (ms)
Figure 5. Simulated phase difference between vein and tissue for various oxygenation levels at (a) 3T and (b)
7T. Black arrows indicate the range of TE's used in our GRE acquisition for each field strength, and the black
dotted line is at a phase difference of pi.
Filtered image Ph(xy)
LPF
p0 (xy)
Pf (XY) Ph ,(xy) (Complex division)
C High-pass filtered image p/x,y)
Figure 6. Schematic for high-pass filtering of phase images from GRE acquisition. (a) Magnitude and phase of
original GRE image. White arrow illustrates an example of phase-wrapping. (b) Low-pass filtered magnitude and
phase. Notice that the phase-wrapping artifact is still present because it is not a physical attribute of the complex
image. (c) Final high-pass filtered phase image after complex division as proposed in [32].
3.1.2 High-pass filtering of phase images at 3T to remove background
inhomogeneities
Background field inhomogeneities cause low-frequency spatial variations in the gradient
echo phase image. These background phase effects must be removed before quantitative
measurements can be made. At 3T, the gradient-echo phase images are effectively high-pass
Original image po(xy)
28
filtered by dividing the original complex signal by a low-pass filtered version of the image (Fig
5) [36]. The low-pass filter is implemented with a 32 x 32 pixel 2D Hanning filter in k-space, as
proposed by Wang et al [36]. This technique removes phase-wraps in the phase image, and the
resulting background tissue has more homogenous phase with mean value of approximately zero.
3.2 Arterial spin labeling acquisition at 3T
We acquired cerebral blood flow maps using the PICORE-Q2TIPS acquisition [28, 30]
described in Table 2. For each scan, 90 control-tag pairs were averaged to generate the perfusion
maps. Note that the ASL sequence has lower in-plane resolution and twice the slice thickness of
the FLASH scans. We matched the coverage of the ASL scans to that of the GRE acquisition
and selected the appropriate slice to measure local perfusion in our analysis.
Table 2. PICORE-Q2TIPS ASL sequence parameters at 3T
Sequence epfid2dl Acquisition time (min) 9:03
TR (ms) 2300 Field of view (mm) 220 x 220
TI1 /T12 (Ms) 700 / 1800 Resolution (mm) 2.0 x 2.0 x 4.0
TE (ms) 25 Bandwidth per pixel 1570
(Hz/pix)
3.3 Quantification of Yv and CMRO2
Candidate gray matter veins for our measurements with were identified manually through
several gradient echo slices (Fig 5a). The appropriate vessel geometry was confirmed using a
sagittal or coronal view of the selected vein (Fig 1b). To measure APvein-tissu, for each TE, we
used the maximum phase value inside the vein for 'Pvein to avoid partial-volume effects (Fig 5b).
Partial-volume effects occur when signal for several tissue types are averaged within a voxel. Y,
was calculated only for vessels that demonstrated a robust fit of A Ovein,-issue across TE's, with R2 >
0.95 (Fig 5d).
Local perfusion for each vein analyzed was analyzed by averaging CBF values from a 6.0
x 6.0mm region in the appropriately matched CBF slice (Fig 5b). Regional CMRO 2 was then
calculated for each candidate vessel using the measured Yv and local CBF.
3.4 Extension to high field imaging at 7T
Imaging at 7T offers significant improvements to SNR that allow for higher resolution
acquisitions. However, main field and radiofrequency (RF) field inhomogeneities and
background susceptibility gradients pose more difficult problems at high field. Here we present
our methods at 7T, which include different acquisition parameters and more aggressive filtering
to deal with phase-wrapping and increased field inhomogeneities.
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Figure 7. (a) Magnitude of a GRE axial slice, with region of interest (ROI) containing candidate vein highlighted in
yellow box. (b) Corresponding CBF map from ASL acquisition. Magenta box indicates region over which
perfusion values were averaged to quantify local perfusion for vessel identified in 6a. (c) Magnitude and phase ROI
of selected vessel. Note the bright contrast of the vessel in the phase image. (d) Fit of measured A(Pveintissue across
several echo times to quantify local AB.
3.4.1 Acquisition parameters for GRE and ASL at 7T
We acquired 32 axial slices with the 3D GRE sequence described in Table 3a. Note that
we reduced both the in-plane resolution and slice thickness, and used a shorter set of TE's to
4
R2 of fit = 0.99
3
2
1 AB
2mm
32
avoid phase wraps as discussed previously (Fig 4b). CBF maps were created using the ASL
sequence described in Table 4a.
Table 3.
a. GRE sequence parameters at 7T
Sequence swi3dlr
TR (ms) 26
TE (ms) 6, 10, 14
Flip Angle (deg) 15
Acquisition time (min)
Field of view (mm)
Resolution (mm)
Bandwidth per pixel
(Hz/pix)
4:10
168 x 192
0.33 x 0.33 x 1.0
130
b. PICORE-Q2TIPS ASL sequence parameters at 7T
Sequence ep4l4A2dl Acquisition time (min) 8:42
TR (ms) 2300 Field of view (mm) 192 x 192
TI, /T12 (Ms) 700 / 1800 Resolution (mm) 2.0 x 2.0 x 4.0
TE (ms) 16 Bandwidth per pixel 2265
(Hz/pix)
3.4.2 High-pass filtering of phase images at 7T
At 7T, we first unwrapped phase images using FSL prelude, a fast, automated phase
unwrapping algorithm based on a region merging approach [37]. Phase images were effectively
high-pass filtered by subtracting a smoothed version of the phase from the original image [38].
Smoothing was done in k-space with a Gaussian low-pass filter of standard deviation a = 4.
GRE images with an ROI around a candidate vessel are illustrated in Fig 6.
34
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Figure 8. (a, b) Magnitude and unwrapped phase of GRE acquisition at 7T. Yellow box indicates vessel of
interest. (c, d) Magnitude and phase ROI of candidate vessel at 7T.
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Chapter 4
Results
4.1 Measurements of Y, and CMRO2 at 3T
We quantified Y, and CMRO2 in 9 healthy, young volunteers (5 male, 4 female) aged 23-
32 at 3T. Data was acquired on a Siemens 3T Tim Trio 60 cm whole-body MRI. All scanning
was performed under informed consent with the approval of the Institutional Review Board.
4.1.1 Study averages at 3T
For each subject, we quantified Y, and local CMRO 2 for at least 5 candidate veins in the
gray matter. These measurements were averaged for each subject, and study means are
presented in Table 4. Our mean venous oxygenation (58.5%) and CBF (52.5 ml/100g/min) lie
within the normal physiological range reported previously [39, 40].
Table 4. Study averages of Y,, CBF, and CMRO 2 at 3T (n = 9)
YC BF CMRO 2(ml/100g/min) (pmol/100g/min)
58.5 ± 2.3 52.5 ± 3.9 182 + 15
4.1.2 Comparison of measured CMRO2 to literature values
The mean CMRO2 value (182 ptmol/100g/min) we measure lies in the expected range
from values reported in literature by PET [41-45] and the TRUST MRI method [12] as depicted
in Fig 8. Currently, TRUST is the only other MRI-based technique to quantify CMRO 2.
TRUST uses a tagging scheme similar to ASL for T2 measurements in the sagittal sinus, which is
the main draining vein located behind the brain [39]. These T2 measurements are then used to
quantify whole-brain Yv through a calibration curve based on a known relationship between
oxygenation and blood T2.
Because TRUST is a whole-brain technique, its measured CMRO2 values represent an
average of metabolism in gray matter and white matter tissue [12]. Gray matter tissue has been
shown to have higher metabolism than white matter tissue [41]. Our CMRO2 measurement is
slightly higher than that of TRUST, which is consistent with our focus on gray matter vessels in
this study.
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Figure 9. Comparison of measured CMRO2 values to those reported by PET and MRI techniques. Our method is
reported as phase-based regional oxygen metabolism (PROM).
4.2 Preliminary measurements at 7T
The improved SNR at 7T allowed us to dramatically push the resolution of our technique
with a 1/5 reduction in voxel size in the GRE acquisition. We were also able to increase our
coverage of the brain and quantify more vessels per subject with similar scan duration at 7T
compared to 3T (Table 5a). Six subjects were scanned at 7T, with a mean oxygenation across
the subjects of 59.7% (Table 5b). This matches our measured average for Y, at 3T. We were
only able to quantify CMRO2 in one subject at 7T because of difficulties in EPI stability and
field inhomogeneities in the inversion pulse. Our CMRO 2 in one subject of 162 pmol/100g/min
also lies within the expected range.
Table 5.
a. Comparison of GRE acquisitions at 3T and 7T
3T 7T
Resolution (mm)
Acquisition time (min)
Average # vessels per subject
0.5 x 0.5 x 2.0
5:53
5.8
0.33 x 0.33 x 1.0
4:10
14.0
b. Measurements of Y, and CMRO2 at 7T
Mean Y, (n = 6): 59
CMRO2 in one subject: 16
.7 ±4.2 %
2 pmol/100g/min
Chapter 5
Discussion
We have developed a new MRI method to quantify in vivo local Y, and CMRO 2 in the
brain and demonstrated the method with imaging studies on human volunteers. These
physiological parameters are currently unavailable using noninvasive MRI techniques, and have
the potential to provide novel information about brain function and disease. Our technique is
powerful because it uses standard GRE and ASL sequences already available on most clinical
scanners to make these measurements. Our measurements of Y, and CMRO 2 at 3T lie within the
physiological range and show promising results when compared to other techniques.
Our method is intrinsically resolution dependent and can take advantage of improved
SNR at 7T for higher spatial resolution. A critical benefit of the higher resolution is mitigation
of partial-volume effects, i.e. mixing of tissue types within a voxel, which can distort phase
measurements that underlie our quantification of Yv. This improved spatial resolution allows us
to analyze smaller cerebral vessels expected to be more indicative of regional brain function and
enables a larger number of vessels to be included in the processing. We successfully developed
an acquisition scheme and appropriate post-processing filtering to address the more difficult
inhomogeneities and background susceptibility effects at high field. Here we demonstrated
imaging with a 1/5 reduction in voxel size compared to 3T and dramatically increased the
number of vessels analyzed for Y, estimates, with promising physiological measurements at 7T.
One current limitation of our technique is its dependence on vessel geometry and
orientation. To simplify the quantification of susceptibility, we have focused on vessel segments
that can be approximated with an infinite cylinder and that are parallel to the main magnetic
field. This condition naturally limits the set of vessels that can be analyzed with the current
technique, and may introduce bias to our Y, measurements depending on how well the infinite-
cylinder approximation holds. In follow-up work to this thesis, we propose a detailed analysis
on the effect of vessel length, tilt, and geometry on Yv in the future to understand this potential
bias.
To further address this vessel geometry limitation, we also suggest the development of
quantitative susceptibility mapping (QSM) specifically for the curved vessel problem, much
along the line of techniques currently being developed in the field [17-22] with applications to
iron quantification in the brain. In particular, LI-weighted regularization of the inversion of field
maps to susceptibility maps have been successful for mapping of regional iron deposition [38].
From magnetostatics, we know that susceptibility shifts cause perturbations in the main magnetic
field and T2* decay. Because susceptibility shifts that are not manifested in T2* images are
spatially smooth, and therefore "sparse" in an appropriate basis set, we can use Li-norm
regularization to fit for a spatial susceptibility distribution [46]. This is framed as a minimization
problem using a conjugate gradient optimization technique. We therefore suggest the use of
QSM to extend our analysis of Y, to a larger set of vessels with arbitrary orientation and
geometry.
Another limitation of our method is the relatively low resolution of CBF maps from
which local perfusion values are quantified. ASL is intrinsically a low-resolution technique
because the perfusion weighting in the ASL difference signal derives from small CBF-dependent
changes between control and tag images. At 3T, our ASL acquisition uses in-plane resolution
that is four times lower than the GRE sequence and has twice the slice thickness. In our analysis,
we selected gray matter ROIs for average CBF corresponding to a vein identified in the GRE
images. We selected this gray matter ROI to avoid partial-volume effects from white matter
CBF, based on the contrast available in the perfusion map. However, it is likely that our
technique still averages gray and white matter perfusion in quantifying local CBF due to its low
resolution and averaging for regional CBF. Further work on characterizing these effects on our
estimates is likely to be valuable.
In addition, although we calculated regional CBF using an ROI corresponding to an
identified vessel, we do not know if this local ROI in fact corresponds to the tissue or territory
that the vein is draining. Identifying the appropriate draining territory for a vein in the perfusion
map is a more difficult task. This region of drainage likely depends on vessel size and its
position within the vasculature, and determines the optimal ROI for accurate local CBF
measurements. This is an interesting physiology question that we propose as valuable and high-
impact future work. An understanding of vessel drainage would allow us to accurately match
perfusion values in tissue to appropriate veins throughout the whole brain, and potentially extend
our method to create maps of local CMRO2 in the brain.
An important next step in the future development of the proposed technique is to verify
the ability of our Y, and CMRO2 measurements to detect local and global physiological changes
in the brain. We will assess the ability of our maps to detect localized neural activations in
response to stimuli such as a visual or motor task. Global changes in Y, and CMRO2 will also be
investigated using gas experiments such as hypercapnia. A key clinical collaborator at the
Athinoula A. Martinos Center for Biomedical Imaging, Caterina Maneiro, M.D., recently
submitted a grant proposal to the Multiple Sclerosis (MS) Society for a study in which we plan to
assess physiological changes in patients with MS. Our method was proposed as an ideal
candidate to investigate the chronic cerebrospinal venous insufficiency hypothesis, which
suggests that venous drain blockage in the brain is critical to the pathology of MS [47]. These
experiments are important to validate our Y, and CMRO 2 measurements as a method for
functional imaging of neural activation and disease states of the brain.
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